Literature DB >> 18843654

Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence.

Laura Amato1, Silvia Minozzi, Marina Davoli, Simona Vecchi, Marica M F Ferri, Soraya Mayet.   

Abstract

BACKGROUND: Maintenance treatments are effective in retaining patients in treatment and suppressing heroin use. Questions remain regarding the efficacy of additional psychosocial services offered by most maintenance programs.
OBJECTIVES: To evaluate the effectiveness of any psychosocial plus any agonist maintenance treatment versus standard agonist treatment for opiate dependence in respect of retention in treatment, use of substances, health and social status. SEARCH STRATEGY: We searched: Cochrane Drugs and Alcohol Group's Register of Trials (February 2008), Cochrane Central Register of Controlled Trials (CENTRAL - The Cochrane Library issue 1, 2008), MEDLINE (January 1966 to February 2008), EMBASE (January 1980 to February 2008), CINAHL (January 2003-February 2008), PsycINFO (January 1985 to April 2003), reference lists of articles. SELECTION CRITERIA: Randomised studies comparing any psychosocial plus any agonist with any agonist alone intervention for opiate dependence. DATA COLLECTION AND ANALYSIS: Three reviewers independently assessed trial quality and extracted data. MAIN
RESULTS: Twenty eight trials, 2945 participants, were included. These studies considered twelve different psychosocial interventions and three pharmacological maintenance treatments. Comparing any psychosocial plus any maintenance pharmacological treatment to standard maintenance treatment, results do not show benefit for retention in treatment, 23 studies, 2193 participants, Relative Risk (RR) 1.02 (95% CI 0.97 to 1.07), use of opiate during the treatment, eight studies, 681 participants, RR 0.86 (95% CI 0.65 to 1.13), compliance, three studies, MD 0.43 (95% CI -0.05 to 0.92), psychiatric symptoms, four studies, MD 0.02 (-0.19 to 0.23), depression, four studies, MD -1.30 (95% CI -3.31 to 0.72) and results at follow up as number of participants still in treatment at the end of the follow-up , 289 participants, RR 0.91 (95% CI 0.77 to 1.06). In spite of results at follow up as number of participants abstinent at the end of the follow-up, five studies, 232 participants, show a benefit in favour of the associated treatment RR1.15 (95% CI 1.01 to 1.32). The remaining outcomes were analysed only in single studies considering a limited number of participants.Comparing the different psychosocial approaches, results are never statistically significant for all the comparisons and outcomes. AUTHORS'
CONCLUSIONS: Results suggest that adding any psychosocial support to maintenance treatments improve the number of participants abstinent at follow up; no differences for the other outcome measures. Data do not show differences between different psychosocial interventions also for contingency approaches, contrary to all expectations. Duration of the studies was too short to analyse relevant outcomes such as mortality.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18843654     DOI: 10.1002/14651858.CD004147.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  19 in total

1.  Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.

Authors:  Roger D Weiss; Jennifer Sharpe Potter; David A Fiellin; Marilyn Byrne; Hilary S Connery; William Dickinson; John Gardin; Margaret L Griffin; Marc N Gourevitch; Deborah L Haller; Albert L Hasson; Zhen Huang; Petra Jacobs; Andrzej S Kosinski; Robert Lindblad; Elinore F McCance-Katz; Scott E Provost; Jeffrey Selzer; Eugene C Somoza; Susan C Sonne; Walter Ling
Journal:  Arch Gen Psychiatry       Date:  2011-11-07

2.  Clinical risk factors for death after release from prison in Washington State: a nested case-control study.

Authors:  Ingrid A Binswanger; Marc F Stern; Traci E Yamashita; Shane R Mueller; Travis P Baggett; Patrick J Blatchford
Journal:  Addiction       Date:  2016-03       Impact factor: 6.526

3.  Counseling and directly observed medication for primary care buprenorphine maintenance: a pilot study.

Authors:  Brent A Moore; Declan T Barry; Lynn E Sullivan; Patrick G Oʼconnor; Christopher J Cutter; Richard S Schottenfeld; David A Fiellin
Journal:  J Addict Med       Date:  2012-09       Impact factor: 3.702

4.  A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS): rationale, design, and methodology.

Authors:  Roger D Weiss; Jennifer Sharpe Potter; Scott E Provost; Zhen Huang; Petra Jacobs; Albert Hasson; Robert Lindblad; Hilary Smith Connery; Kristi Prather; Walter Ling
Journal:  Contemp Clin Trials       Date:  2010-01-29       Impact factor: 2.226

5.  HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.

Authors:  Frederick L Altice; R Douglas Bruce; Gregory M Lucas; Paula J Lum; P Todd Korthuis; Timothy P Flanigan; Chinazo O Cunningham; Lynn E Sullivan; Pamela Vergara-Rodriguez; David A Fiellin; Adan Cajina; Michael Botsko; Vijay Nandi; Marc N Gourevitch; Ruth Finkelstein
Journal:  J Acquir Immune Defic Syndr       Date:  2011-03-01       Impact factor: 3.731

6.  The use of psychotherapeutic interventions by primary care GPs in Ireland in the treatment of their methadone patients: a grounded theory study.

Authors:  K Kenny; A O'Carroll
Journal:  Ir J Med Sci       Date:  2011-08-18       Impact factor: 1.568

7.  Randomized trial of standard methadone treatment compared to initiating methadone without counseling: 12-month findings.

Authors:  Robert P Schwartz; Sharon M Kelly; Kevin E O'Grady; Devang Gandhi; Jerome H Jaffe
Journal:  Addiction       Date:  2012-02-11       Impact factor: 6.526

Review 8.  Methadone deaths: risk factors in pain and addicted populations.

Authors:  Vania Modesto-Lowe; Donna Brooks; Nancy Petry
Journal:  J Gen Intern Med       Date:  2010-01-20       Impact factor: 5.128

9.  Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence.

Authors:  Wilfrid Noel Raby; Kenneth M Carpenter; Jami Rothenberg; Adam C Brooks; Huiping Jiang; Maria Sullivan; Adam Bisaga; Sandra Comer; Edward V Nunes
Journal:  Am J Addict       Date:  2009 Jul-Aug

10.  A method to diagnose opioid dependence resulting from heroin versus prescription opioids using the Composite International Diagnostic Interview.

Authors:  Jennifer S Potter; Kristi Prather; Frankie Kropp; Mimmie Byrne; C Rollynn Sullivan; Nadia Mohamedi; Marc L Copersino; Roger D Weiss
Journal:  Contemp Clin Trials       Date:  2010-01-14       Impact factor: 2.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.